Log In
Print
BCIQ
Print
Print this Print this
 

AzaSite Xtra (ISV-405)

  Manage Alerts
Collapse Summary General Information
Company InSite Vision Inc.
DescriptionDurasite formulation of azithromycin (2%)
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentPreclinical
Standard IndicationBacterial infection
Indication DetailsTreat ocular infections
Regulatory Designation

Partner

Nicox S.A.; Senju Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$40.3M

$3.0M

$13.8M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today